Quercetin in Coronary Artery By-pass Surgery

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montreal Heart Institute
• Treatments: Quercetin

Criteria

Inclusion Criteria:

• to be able to speak French or English;

• to be able to give free and enlighten consent;

• be hospitalized and waiting for a cardiac surgery of revascularization;

• to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.

Exclusion Criteria:

• to be in a stable state without MI in the last 30 days;

• have a cardiac surgery concomitant to the cardiac surgery of revascularization;

• have an infection in the last 30 days;

• to have renal insufficiency (GFR less than 30);

• to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);

• to have a known cirrhosis;

• to have a past history of breast cancer or other tumors estrogen-dependent;

• to be intolerant to flavonoids, niacine or ascorbic acid;

• take quinolone;

• need for a quinolone during post-op;

• not being able to give a free and enlighten consent;

• not being able to speak French of English;

• take quercetin as a supplement.